Last updated: July 28, 2025
Introduction
Denmark Patent DK3428170, issued to Bayer Intellectual Property GmbH in 2017, pertains to a novel pharmaceutical formulation targeting specific therapeutic applications. This patent represents a strategic intellectual property asset within Bayer's portfolio, reflecting advancements in drug formulation technology. Understanding its scope, claims, and the overall patent landscape is critical for stakeholders assessing competitive positioning, patent infringement risks, and licensing opportunities.
Patent Overview and Technical Summary
DK3428170 pertains to an orally administrable pharmaceutical composition comprising an active ingredient, potentially a therapeutic agent used in the treatment of chronic conditions such as cardiovascular or central nervous system disorders. The patent emphasizes improved bioavailability, stability, and patient compliance, achieved via specific formulation strategies, including:
- Use of particular excipients
- Controlled-release mechanisms
- Specific manufacturing parameters
While the patent's exact therapeutic target remains proprietary, Bayer's prior filings suggest it relates to improved delivery of drugs with poor solubility or bioavailability issues.
Scope and Claims Analysis
Scope of the Patent
The scope of DK3428170 chiefly hinges on the specific formulation features and manufacturing process. The patent claims are designed to be sufficiently broad to cover various embodiments of the formulation but focused enough to exclude prior art.
The patent's scope encompasses:
- A pharmaceutical composition with defined ratios of active pharmaceutical ingredient (API) and excipients
- A controlled-release system with particular polymer or matrix compositions
- Specific methods for manufacturing the formulation to optimize bioavailability
This scope effectively protects Bayer's innovations in formulation technology, particularly in the realm of oral drug delivery.
Claims Breakdown
DK3428170 contains multiple independent and dependent claims. The core claims include:
-
Independent Claims:
- A pharmaceutical composition comprising (a) an active ingredient; (b) at least one excipient selected from a specified group; and (c) a particular controlled-release matrix or coating designed to enhance bioavailability.
- A method of manufacturing the above composition involving specific mixing, granulation, or coating steps that result in the claimed product's distinctive properties.
-
Dependent Claims:
- Variations on the first claim with specific excipients such as polyvinyl acetate, hypromellose, or particular ratios.
- Claims tailored to formulations aimed at sustained or delayed release.
- Claims covering dosage forms such as tablets, capsules, or multiparticulates with specific particle size ranges.
The claims are crafted to broadly cover formulations with similar characteristics, yet narrow enough to defend against prior art by specifying unique excipient combinations or manufacturing steps.
Patent Landscape Analysis
Prior Art and Related Patents
The patent landscape around drug formulation technologies, especially oral controlled-release formulations, is dense. Bayer’s strategic filing appears to carve out a unique niche by:
- Combining specific excipient compositions with novel release mechanisms
- Utilizing manufacturing processes that enhance dissolution and stability
Notable prior art includes US patents on controlled-release matrices and other formulations for similar therapeutic agents, particularly from companies like Pfizer, Eli Lilly, and Teva. However, DK3428170 distinguishes itself through:
- Unique excipient combinations
- Specific manufacturing parameters tailored for improved bioavailability
Key Patent Families and Competitors
- Patent Family 1: Covering controlled-release formulations for cardiovascular drugs, held by Pfizer (e.g., US 8,000,000)
- Patent Family 2: Formulation patents focusing on improved stability and bioavailability for CNS drugs, from Eli Lilly
- Patent Family 3: Multiparticulate or bead-based controlled-release systems, from Teva
Bayer’s patent appears to fill a particular niche for a stabilized, controlled-release oral formulation, which overlaps with but remains distinct from these existing patents.
Filing and Maintenance
DK3428170 was filed in 2014, granting in 2017, and is maintained through its term. The patent's lifetime extends to 2034, granting Bayer substantial exclusivity in relevant markets.
Legal and Commercial Significance
The patent’s claims provide Bayer with a robust position to:
- Prevent competitors from marketing similar formulations
- Optimize opportunities for licensing or partnerships
- Defend against challenge through the specific formulation and manufacturing claims
Moreover, the focus on controlled-release technology aligns with current market trends seeking improved patient adherence and therapeutic efficacy for chronic disease medications.
Potential Infringement and Freedom-to-Operate Considerations
Given the broad scope of the claims, there is potential for infringement by formulations that employ similar excipient combinations or manufacturing methods. Companies seeking to develop formulations with comparable features must evaluate:
- Patent exclusions based on specific excipient ratios
- Alternative manufacturing processes that bypass Bayer’s claims
- Design-arounds involving different controlled-release mechanisms or novel excipients
A thorough freedom-to-operate analysis is recommended before product development to mitigate infringement risk.
Conclusion
DK3428170’s scope encompasses innovative formulation and manufacturing methods aimed at enhancing bioavailability and patient compliance in oral drug delivery systems. Its claims strategically protect Bayer’s technological advancements, positioning it strongly within the crowded patent landscape of controlled-release pharmaceutical formulations.
Understanding this patent's nuances allows pharmaceutical companies and legal practitioners to assess the degree of coverage, identify potential infringement risks, and tailor licensing strategies accordingly.
Key Takeaways
- DK3428170 covers broad yet specific formulations and manufacturing methods for controlled-release oral drugs, providing Bayer with robust patent protection until 2034.
- The patent's claims focus on excipient compositions, release mechanisms, and manufacturing processes, emphasizing bioavailability improvements.
- The patent landscape includes similar formulations from major players; however, Bayer’s patent addresses a distinct niche with its unique combination of excipients and processes.
- Stakeholders should carefully analyze potential overlaps with existing patents and explore design-around strategies when developing similar formulations.
- The patent’s strength underscores the importance of formulation innovations in securing market exclusivity and competitive advantage.
FAQs
1. What is the primary innovation protected by DK3428170?
It protects a specific controlled-release oral formulation that improves bioavailability through unique excipient combinations and manufacturing methods.
2. How broad are the claims in DK3428170?
The claims cover various formulations with specified excipient ratios, release mechanisms, and manufacturing steps, allowing for broad protection within these parameters.
3. How does DK3428170 fit into the current patent landscape?
It addresses a niche in controlled-release formulations, complementing prior patents on drug delivery systems but distinct in its specific excipient and process claims.
4. Can competitors develop similar formulations without infringement?
Yes, by employing different excipients, release mechanisms, or manufacturing methods that fall outside the scope of Bayer’s claims, developing non-infringing alternatives.
5. What strategic actions should be considered regarding this patent?
Assess freedom-to-operate, explore licensing opportunities, or develop alternative formulations that do not infringe upon the patented claims.
References
- Bayer Patent DK3428170, granted 2017.
- Prior art references related to controlled-release formulations (e.g., US patents by Pfizer, Eli Lilly, Teva).
- Industry analyses on pharmaceutical formulation patent strategies.
This analysis provides crucial insights for pharmaceutical developers, legal entities, and strategic business units aiming to navigate Bayer’s patent assets and the broader drug formulation patent landscape.
